Related Experiment Video

Updated: Feb 25, 2026

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.3K

Coffee Ingestion Suppresses Hyperglycemia in Streptozotocin-Induced Diabetic Mice

Misato Kobayashi1, Takao Kurata1, Yoshiki Hamana1

  • 1Department of Applied Molecular Bioscience, Graduate School of Bioagricultural Sciences, Nagoya University.

Journal of Nutritional Science and Vitaminology
|August 1, 2017
PubMed

Insights

Coffee consumption may prevent type 2 diabetes by protecting pancreatic beta-cells. This effect appears to require both caffeine and other coffee components, not just caffeine alone.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Coffee consumption is linked to reduced type 2 diabetes risk in humans.
  • The precise mechanisms underlying coffee's protective effects on pancreatic beta-cells remain largely unknown.

Purpose of the Study:

  • To investigate the impact of coffee on pancreatic beta-cells in the context of streptozotocin (STZ)-induced diabetes in mice.
  • To determine whether coffee, caffeine, or decaffeinated coffee influences STZ-induced hyperglycemia and beta-cell function.

Main Methods:

  • Mice were administered streptozotocin (STZ) to induce diabetes.
  • Experimental groups received coffee, caffeine, or decaffeinated coffee, while a control group received water.
  • Serum glucose levels, water intake, and pancreatic insulin content were measured.
  • The effect of coffee on established STZ-induced diabetes was also assessed.

Main Results:

  • Coffee consumption significantly lowered serum glucose concentrations and water intake post-STZ injection compared to water.
  • Caffeine alone did not significantly alter glucose levels or water intake.
  • Decaffeinated coffee showed a trend towards lowering serum glucose.
  • Pancreatic insulin content tended to be higher in mice consuming coffee or decaffeinated coffee.
  • Coffee ingestion suppressed hyperglycemia in mice with pre-existing STZ-induced diabetes.

Conclusions:

  • Coffee ingestion demonstrates a protective effect against STZ-induced diabetes development and progression.
  • The observed benefits appear to stem from a combination of caffeine and other compounds present in decaffeinated coffee, rather than caffeine alone.
  • Coffee may play a role in preserving pancreatic beta-cell function and insulin content, contributing to diabetes prevention.
Keywords:
caffeinecoffeediabeteshyperglycemiastreptozotocin

More Related Videos

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas04:41

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

1.0K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

72.1K

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
669
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
729
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
780
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
756